Teratogen use in women of childbearing potential: An intervention study

Journal of the American Board of Family Medicine

Volumn 24, Issue 3, 2011, Pages 262-271

  Morrical Kline, Karie A ^a   Walton, Alison M ^a,b   Guildenbecher, Tracey M ^a  

^a St Vincent Joshua Max Simon Primary Care Center   (United States)

^b BUTLER UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; HMG CoA reductase inhibitor; Pregnancy; Teratogens

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TERATOGENIC AGENT;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; INTERVENTION STUDY; MEDICAL RECORD REVIEW; PATIENT SAFETY; PREGNANCY; PROFESSIONAL KNOWLEDGE; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL COMPETENCE; CONFIDENCE INTERVALS; DATA COLLECTION; EDUCATIONAL STATUS; FEMALE; HUMANS; MATERNAL WELFARE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79955850449     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2011.03.100198     Document Type: Article

References (13)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e1-e170.
2. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010; 33(Suppl 1):S11-S61.
3. Buhimschi CS, Weiner CP. Medication in pregnancy and lactation. Part 1. Teratology. Obstet Gynecol 2009;113:166-88.
4. Martin U, Foreman MA, Travis JC, Casson D, Coleman JJ. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507-11.
5. Bowen ME, Ray WA, Arbogast PG, Ding H, Cooper WO. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008;198:291.e1-291.e5.
6. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354(23):2443-51. (Pubitemid 43855047)
7. US Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. Available at: http://www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM053113/ UCM053113. Accessed April 20, 2010.
8. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008;143:169-236.
9. Patel C, Edgerton L, Flake D. What precautions should we use with statins for women of childbearing age? J Fam Pract 2006;55(1):75-7.
10. US Food and Drug Administration. Summary of proposed rule on pregnancy and lactation labeling. Available at: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm. Accessed December 22, 2010.
11. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52. (Pubitemid 37553153)
12. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. National Center for Health Statistics. Vital Health Stat 23 2010;(29): 1-44.
13. Hamilton MB. SuperSurvey-Online Survey Response Rates and Times: Background and Guidance for Industry. Available at: http://secure.supersurvey. com/papers/supersurvey-white-paper-response-rates.pdf, Longmont, CO: Ipathia, Inc. 2009.